PL367896A1 - Kompozycje farmaceutyczne zawierające krzemionkę koloidalną - Google Patents
Kompozycje farmaceutyczne zawierające krzemionkę koloidalnąInfo
- Publication number
- PL367896A1 PL367896A1 PL02367896A PL36789602A PL367896A1 PL 367896 A1 PL367896 A1 PL 367896A1 PL 02367896 A PL02367896 A PL 02367896A PL 36789602 A PL36789602 A PL 36789602A PL 367896 A1 PL367896 A1 PL 367896A1
- Authority
- PL
- Poland
- Prior art keywords
- silicon dioxide
- colloidal silicon
- pharmaceutical compositions
- disintegrant
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0123400.4A GB0123400D0 (en) | 2001-09-28 | 2001-09-28 | Organic compounds |
PCT/EP2002/010890 WO2003028705A1 (en) | 2001-09-28 | 2002-09-27 | Pharmaceutical compositions comprising colloidal silicon dioxide |
Publications (2)
Publication Number | Publication Date |
---|---|
PL367896A1 true PL367896A1 (pl) | 2005-03-07 |
PL209704B1 PL209704B1 (pl) | 2011-10-31 |
Family
ID=9922916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL367896A PL209704B1 (pl) | 2001-09-28 | 2002-09-27 | Kompozycja farmaceutyczna w postaci tabletki do sporządzania zawiesin oraz sposób wytwarzania tabletki do sporządzania zawiesin zawierającej 40-O-(2-hydroksy)etylo-rapamycynę |
Country Status (31)
Country | Link |
---|---|
US (4) | US20040254210A1 (pl) |
EP (2) | EP1432408B8 (pl) |
JP (2) | JP2005507897A (pl) |
KR (1) | KR100626785B1 (pl) |
CN (3) | CN101912392A (pl) |
AR (2) | AR036643A1 (pl) |
AT (1) | ATE485813T1 (pl) |
BR (2) | BR0212922A (pl) |
CA (1) | CA2458455C (pl) |
CO (1) | CO5390072A1 (pl) |
CY (2) | CY1111119T1 (pl) |
DE (1) | DE60238131D1 (pl) |
DK (2) | DK2193788T3 (pl) |
EC (1) | ECSP024323A (pl) |
ES (2) | ES2354687T3 (pl) |
GB (1) | GB0123400D0 (pl) |
HK (2) | HK1141239A1 (pl) |
HU (1) | HU229991B1 (pl) |
IL (2) | IL160498A0 (pl) |
MX (1) | MXPA04002814A (pl) |
MY (1) | MY150060A (pl) |
NO (1) | NO333892B1 (pl) |
NZ (2) | NZ531599A (pl) |
PE (1) | PE20030602A1 (pl) |
PL (1) | PL209704B1 (pl) |
PT (2) | PT2193788E (pl) |
RU (1) | RU2322970C2 (pl) |
SI (1) | SI1432408T1 (pl) |
TW (1) | TWI242449B (pl) |
WO (1) | WO2003028705A1 (pl) |
ZA (1) | ZA200401300B (pl) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
CN100522967C (zh) | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | 含磷化合物及其应用 |
CN100415233C (zh) * | 2002-09-17 | 2008-09-03 | 惠氏公司 | 口服制剂 |
JPWO2004035089A1 (ja) * | 2002-10-09 | 2006-02-09 | 協和醗酵工業株式会社 | ホルモン依存性癌の治療剤 |
DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
ES2380950T3 (es) * | 2005-06-09 | 2012-05-21 | Hansa Medical Ab | Uso de la proteinasa IdeS ( de S, pyogenes) para tratar enfermedades autoinmunitarias y rechazo de injerto |
CA2669415A1 (en) * | 2006-11-14 | 2008-05-22 | Ariad Pharmaceuticals, Inc. | Solid dosage form comprising ap23573 |
MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
EA201591353A1 (ru) * | 2008-05-02 | 2016-01-29 | Джилид Сайэнс, Инк. | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента |
CN101444503B (zh) * | 2008-12-31 | 2011-02-02 | 江苏大学 | 一种水飞蓟宾高效长效制剂及其制法 |
CN101439025B (zh) * | 2008-12-31 | 2011-05-11 | 江苏大学 | 一种水飞蓟素高效长效制剂及其制法 |
CN101444494B (zh) * | 2008-12-31 | 2011-03-30 | 江苏大学 | 难溶性药物高效长效缓释制剂及其制法 |
PL2389070T3 (pl) * | 2009-01-21 | 2014-01-31 | Mylan Inc | Preparaty węglanu lantanu ulegające rozpadowi |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
JP5779591B2 (ja) | 2009-12-22 | 2015-09-16 | アッヴィ・インコーポレイテッド | Abt−263カプセル剤 |
US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
WO2012071374A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Methods of treatment using selective bcl-2 inhibitors |
US8722657B2 (en) | 2010-11-23 | 2014-05-13 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
DE102011052396A1 (de) * | 2011-08-04 | 2013-02-07 | Gelita Ag | Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung |
KR101151890B1 (ko) * | 2011-08-11 | 2012-05-31 | 동아제약주식회사 | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 |
SG11201400730VA (en) | 2011-10-06 | 2014-06-27 | Novartis Ag | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
CN102793673A (zh) * | 2012-09-07 | 2012-11-28 | 中国药科大学 | 一种小檗碱磷脂复合物固体分散体及其制备方法 |
AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事(everolimus)之醫藥組合物 |
CA2929181A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
CN103610646B (zh) * | 2013-12-05 | 2015-07-15 | 江苏奥赛康药业股份有限公司 | 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂 |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
WO2016135740A1 (en) | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
WO2017018433A1 (ja) | 2015-07-28 | 2017-02-02 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法 |
US20190290631A1 (en) | 2016-05-27 | 2019-09-26 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof |
RS63751B1 (sr) | 2016-09-30 | 2022-12-30 | Salix Pharmaceuticals Inc | Čvrsti disperzioni oblici rifaksimina |
CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
US11504333B2 (en) | 2017-07-05 | 2022-11-22 | Novartis Ag | Pharmaceutical composition |
CN108125918B (zh) * | 2018-01-12 | 2020-06-23 | 杭州中美华东制药有限公司 | 依维莫司药物组合物 |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
US5211958A (en) * | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
US4920102A (en) | 1988-04-18 | 1990-04-24 | Eli Lilly And Company | Method for treating gastrointestinal disorders |
IT1246383B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
SK281920B6 (sk) | 1991-07-03 | 2001-09-11 | Pharmacia And Upjohn Company | Farmaceutická tableta na báze ionexových živíc a spôsob jej výroby |
US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
IL129547A (en) | 1994-10-26 | 2001-01-11 | Novartis Ag | Pharmaceutical compositions comprising a macrolide and an acid |
FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
DE19544507B4 (de) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
KR20040058360A (ko) * | 1996-02-29 | 2004-07-03 | 후지사와 야꾸힝 고교 가부시키가이샤 | 합성 감미료 |
JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
US6056974A (en) * | 1996-04-26 | 2000-05-02 | Shionogi & Co., Ltd. | Rapid-release S1452 tablets |
GB2318511A (en) | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
AU728754B2 (en) | 1996-11-12 | 2001-01-18 | Pharmacia & Upjohn Ab | Compact member comprising a plurality of porous cellulose matrices, (PCMs), method of manufacturing and use thereof |
US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
HUP0003341A3 (en) | 1997-06-13 | 2001-03-28 | Wyeth Corp | Rapamycin formulations for oral administration |
WO1999049863A1 (fr) | 1998-03-26 | 1999-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Preparations a liberation prolongee |
FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
AU2944700A (en) * | 1999-03-15 | 2000-10-04 | Kaken Pharmaceutical Co., Ltd. | Quickly disintegrating tablets and process for producing the same |
FR2793690B1 (fr) | 1999-03-30 | 2003-01-03 | Cll Pharma | Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique |
DK1179342T3 (da) * | 1999-05-21 | 2006-07-31 | Kissei Pharmaceutical | Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse |
GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
UA90708C2 (ru) | 2005-02-25 | 2010-05-25 | Ф. Хоффманн-Ля Рош Аг | Таблетки с улучшенной дисперсностью лекарственного вещества |
TWI347942B (en) | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
-
2001
- 2001-09-28 GB GBGB0123400.4A patent/GB0123400D0/en not_active Ceased
-
2002
- 2002-09-26 EC EC2002004323A patent/ECSP024323A/es unknown
- 2002-09-26 AR ARP020103642A patent/AR036643A1/es not_active Application Discontinuation
- 2002-09-26 PE PE2002000948A patent/PE20030602A1/es not_active Application Discontinuation
- 2002-09-27 CO CO02087099A patent/CO5390072A1/es not_active Application Discontinuation
- 2002-09-27 TW TW091122345A patent/TWI242449B/zh not_active IP Right Cessation
- 2002-09-27 CA CA2458455A patent/CA2458455C/en not_active Expired - Lifetime
- 2002-09-27 RU RU2004113205/15A patent/RU2322970C2/ru active
- 2002-09-27 EP EP02774661A patent/EP1432408B8/en not_active Expired - Lifetime
- 2002-09-27 NZ NZ531599A patent/NZ531599A/en not_active IP Right Cessation
- 2002-09-27 US US10/490,089 patent/US20040254210A1/en not_active Abandoned
- 2002-09-27 BR BR0212922-1A patent/BR0212922A/pt not_active IP Right Cessation
- 2002-09-27 EP EP09177889.4A patent/EP2193788B1/en not_active Expired - Lifetime
- 2002-09-27 AT AT02774661T patent/ATE485813T1/de active
- 2002-09-27 PL PL367896A patent/PL209704B1/pl not_active IP Right Cessation
- 2002-09-27 ES ES02774661T patent/ES2354687T3/es not_active Expired - Lifetime
- 2002-09-27 PT PT91778894T patent/PT2193788E/pt unknown
- 2002-09-27 JP JP2003532038A patent/JP2005507897A/ja not_active Withdrawn
- 2002-09-27 CN CN2010101174089A patent/CN101912392A/zh active Pending
- 2002-09-27 CN CNA028190459A patent/CN1561201A/zh active Pending
- 2002-09-27 HU HU0402394A patent/HU229991B1/hu unknown
- 2002-09-27 DK DK09177889.4T patent/DK2193788T3/en active
- 2002-09-27 MX MXPA04002814A patent/MXPA04002814A/es active IP Right Grant
- 2002-09-27 MY MYPI20023631A patent/MY150060A/en unknown
- 2002-09-27 KR KR1020047004628A patent/KR100626785B1/ko active IP Right Grant
- 2002-09-27 WO PCT/EP2002/010890 patent/WO2003028705A1/en active Search and Examination
- 2002-09-27 IL IL16049802A patent/IL160498A0/xx unknown
- 2002-09-27 DE DE60238131T patent/DE60238131D1/de not_active Expired - Lifetime
- 2002-09-27 CN CN2006101159063A patent/CN1951390B/zh not_active Expired - Lifetime
- 2002-09-27 SI SI200230928T patent/SI1432408T1/sl unknown
- 2002-09-27 ES ES09177889.4T patent/ES2560106T3/es not_active Expired - Lifetime
- 2002-09-27 PT PT02774661T patent/PT1432408E/pt unknown
- 2002-09-27 DK DK02774661.9T patent/DK1432408T3/da active
- 2002-09-27 NZ NZ542273A patent/NZ542273A/en not_active IP Right Cessation
- 2002-09-27 BR BRPI0212922-1A patent/BRPI0212922B1/pt unknown
-
2004
- 2004-02-18 ZA ZA200401300A patent/ZA200401300B/en unknown
- 2004-02-19 IL IL160498A patent/IL160498A/en active IP Right Grant
- 2004-03-26 NO NO20041270A patent/NO333892B1/no not_active IP Right Cessation
- 2004-12-15 HK HK10107727.3A patent/HK1141239A1/xx not_active IP Right Cessation
- 2004-12-15 HK HK04109968.5A patent/HK1067036A1/xx not_active IP Right Cessation
-
2008
- 2008-12-04 JP JP2008309431A patent/JP5160386B2/ja not_active Expired - Lifetime
-
2010
- 2010-05-10 US US12/776,711 patent/US20100221331A1/en not_active Abandoned
- 2010-11-30 CY CY20101101091T patent/CY1111119T1/el unknown
-
2011
- 2011-06-13 US US13/158,921 patent/US20110306630A1/en not_active Abandoned
-
2012
- 2012-06-05 US US13/489,396 patent/US8617598B2/en not_active Expired - Lifetime
-
2014
- 2014-08-14 AR ARP140103055A patent/AR097341A2/es unknown
-
2016
- 2016-01-21 CY CY20161100068T patent/CY1117164T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1067036A1 (en) | Pharmaceutical compositions comprising colloidal silicon dioxide | |
AU2002254343A1 (en) | Halo-polymer nanocomposite compositions, methods, and products employing such compositions | |
EP1399414A4 (en) | SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA | |
PL369567A1 (pl) | Pochodne 1,6-naftyrydyny jako środki przeciwcukrzycowe | |
PL370041A1 (pl) | 2,4-dwupodstawione pochodne pirymidynylu do stosowania jako środki przeciwrakowe | |
IL160081A0 (en) | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
IL161857A0 (en) | Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene | |
MXPA03009234A (es) | COMPOSICIONES COSMeTICAS QUE CONTIENEN POLIMEROS DE DISPERSIoN. | |
WO2004060276A3 (en) | Improved sunscreen compositions | |
EP1539122A4 (en) | PHARMACEUTICAL COMPOSITIONS OF AQUEOUS 2,6-DIISOPROPYLPHENOL | |
MXPA03009698A (es) | Vacuna multivalente que comprende un antigeno vih y un antigeno vsh y/o un antigeno vph. | |
HUP0400179A3 (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them | |
PL367179A1 (pl) | Preparaty 3,7-diazabicyklo[3.3.1] jako związki przeciwarytmiczne | |
AU2001275677A1 (en) | 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants | |
EP1449860A4 (en) | NOVEL FLUOROPOLYMER, RESERVE COMPOSITIONS CONTAINING THE SAME, AND NOVEL FLUOROMONOMERS | |
WO2001009122A3 (en) | Serotonergic benzofurans | |
PL370686A1 (pl) | Kompozycje farmaceutyczne zawierające 3,4-propinoperhydropuryny i ich zastosowania do blokowania transmisji neuronowej | |
MXPA03009209A (es) | Formulaciones de 3,7-diazabiciclo-[3.3.1] como compuestos anti-arritmicos. | |
EP1469000A4 (en) | NEW CRYSTALLINE TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVE | |
EP1556022A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITIONS 2,6-DIISOPROPYLPHENOL | |
RU2001102729A (ru) | Формовочный состав для декоративных изделий | |
DE60237360D1 (en) | Glycopeptidantibiotika | |
GB0106603D0 (en) | Laser-markable compositions | |
AU2002233637A1 (en) | Medicinal composition containing 1,3-thiazine derivative | |
AU2002325498A1 (en) | 2,6-dimethylphenol composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
VDSO | Invalidation of derivated patent or utility model |
Ref document number: 388732 Country of ref document: PL Kind code of ref document: A1 |